Antibiotics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antibiotics Market By Product Type (Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycoside, Sulfonamide, And Others), By Spectrum (Broad-Spectrum Antibiotics And Narrow-Spectrum), By Drug Origin (Natural And Synthetic), By Route Of Administration (Oral, Intravenous And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to rising prevalence of infectious diseases and increased consumption of antibiotics in low and middle-income countries

The global antibiotics market was valued at USD 44.20 billion in 2023, growing at a CAGR of 4.91% during the forecast period from 2024 to 2030 to reach USD 58.90 billion by 2030. The antibiotics market is slated to witness prosperity owing to factors such as the rising prevalence of infectious diseases, increased consumption of antibiotics in low and middle-income countries, increased research and development to develop advanced therapies, and a growing geriatric population which is susceptible to the infectious disorder are further expected to result in the appreciable revenue growth in the antibiotics market during the forecast period (2024-2030).

Antibiotics Market Dynamics:

Among the noteworthy drivers of the antibiotics market, the increasing prevalence of infectious diseases that are required to be treated with antibiotics is one of the major factors responsible for accelerating the antibiotics market. Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. From a common cold to COVID-19, the majority of disorders are due to the presence of these foreign ailments. Antibiotics are utilized in treating different infectious disorders such as urinary tract infections, sinus infections, skin, and ear infections among others.

As per CDC, and National Centre for Health Statistics sources, the number of new tuberculosis, salmonella, Lyme disease, and meningococcal disease in the US were 8,916; 58,371; 34,945, and 371 in 2019 respectively.

Moreover, according to the October 2022 report of the World Health Organization (WHO), about 1.5 million people worldwide died because of tuberculosis in 2020, and approximately 10 million people fell ill with TB globally. As per the same source from WHO, of the estimated new cases of tuberculosis in 2020, 1.1 million were in children, and 86% of the TB cases were reported from the 30 high TB burden countries.

Thus, this increased number of infectious disorders will in turn increase the demand for the antibiotics market globally. Furthermore, the increase in the number of infectious disorders also means increased research and developmental activities by major pharmaceutical companies to develop novel therapies, thereby fueling the growth of the antibiotics market in the forecast period of 2024-2030.

According to Pew Charitable Trust, in December 2019, around 41 promising molecules were being investigated for the treatment of serious bacterial infections. Out of these 41 investigational drugs, 17 are in the third phase of the clinical trials or have filed NDA for approval and are expected to be commercialized during the forecast period. In the second half of 2019, four new antibiotic drugs received U.S. FDA approval.

Thus, all the above factors point toward positive market growth in the forecast period of 2024-2030.

The increased infectious disorders and increased R&D activities by pharmaceutical manufacturers also call for supportive governmental policies which will further act as fuel in the growth of the antibiotics market. For instance, BARDA in alliance with the government has extended its support to several companies to aid the development process of new therapies for infectious diseases. Furthermore, supportive government legislation such as the GAIN Act and REVAMP Act is anticipated to expedite the approval process globally.

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the antibiotics market. However, many antibiotics were initially used to treat COVID-19 and are widely prescribed and studied as the COVID-19 remedy. For instance, in March 2020, Pfizer announced positive data for using its azithromycin (Zithromax) drug, along with hydroxychloroquine, in a coronavirus clinical trial performed in France. There was a huge demand for antibiotics during the COVID-19 pandemic.

Furthermore, climate change and urbanization, changing ecosystems, an increase in the geriatric population prone to infectious diseases, and an increasing number of public-private collaborations are other few of the factors that will drive the growth of the antibiotics market during the forecast period from 2024-2030.

However, antibiotic resistance features of the bacteria which are compelling pharmaceutical companies to shift their focus from antibiotics and concentrate on newer technologies and stringent regulatory approvals for antibiotics are a few of the market restraints which will impact the market growth during the forecast period from 2024-2030.

Antibiotics Market Segment Analysis:

Antibiotics Market By Product Type (Cephalosporin, Penicillin, Fluroquinilone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamide, and Others), By Spectrum (Broad-Spectrum Antibiotics and Narrow-Spectrum), By Drug Origin (Natural and Synthetic), By Route of Administration (Oral, Intravenous and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the antibiotics market, penicillin accounted for the largest market share in the base year 2022. This can be ascribed to the largest number of generic manufacturers in the space.

Penicillin is a narrow-range antibiotic that covers gram-positive bacteria and some gram-negative bacteria. Penicillin can be given as an injection as well as an oral tablet or liquid suspension.

Penicillin is one of the oldest antibiotics seen in the market, various new and advanced versions of it are now available in the market, such as Amoxicillin. It is a newer version of penicillin that covers more types of bacteria. Amoxicillin was created by modifying the original chemical structure of penicillin to make it more potent. It is considered a broad-range antibiotic that covers a wider variety of bacteria compared to penicillin.

Penicillin is used in the treatment of throat infections, meningitis, syphilis, and various other infections. Therefore, considering the broad range of diseases that are treated by penicillin and the advantages associated with using penicillin are expected to contribute to the dominant market share.

Asia Pacific is expected to dominate the overall Antibiotics Market:

Among all the regions, Asia-Pacific is expected to lead in revenue generation in the global antibiotics market. This can be ascribed to the increasing prevalence of bacterial infections in the region, increasing usage of antibiotics for various diseases, and the local presence of key market players among other factors in the region.

One of the prominent factors supporting the growth of the Asia-Pacific antibiotics market is the high prevalence rate of infectious diseases across the region. Asia-Pacific particularly South East Asia is a biodiversity hub. However rapid urbanization has led to disturbed ecosystems and a rise in the prevalence of infectious diseases.

According to WHO, Global Tuberculosis Report 2022, Southeast Asia accounted for 43%, and the Western Pacific for 18% of the global burden of TB in 2020.

Furthermore, a growing geriatric population in the Asia-Pacific region is also a factor contributing to the dominant market share.

As per UNFPA, the number of older people in the Asia-Pacific region is rising at an unprecedented rate by 2050, one in four people in Asia and the Pacific will be over 60 years old.

Apart from this, the presence of many regional players in Asia-Pacific for antibiotics manufacturers is also a key factor for the dominance in the market arena.

Therefore, the above-mentioned factors are expected to bolster the growth of the antibiotics market in the Asia-Pacific region during the forecast period.

Antibiotics Market Key Players:

Some of the key market players operating in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Daiichi Sankyo, Astellas Pharma, Melinta Therapeutics Inc., Allergan plc., Basilea Pharmaceutica Ltd, Tetraphase Pharmaceuticals, Spero Therapeutics, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc. and others.

Recent Developmental Activities in the Antibiotics Market:

In October 2022, Sandoz, a Novartis division, acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands namely Zinnat, Zinacef, and Fortum in more than 100 markets, strengthening its position as the world's leading antibiotics company.

In August 2022, Japan-based Otsuka Pharmaceutical has been awarded a grant for up to USD 17.8 million to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson's for patients with drug-susceptible pulmonary tuberculosis (DS-TB).

Key Takeaways from the Antibiotics Market Report Study

• Market size analysis for current antibiotics market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antibiotics market.
• Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global antibiotics market.
• Various opportunities were available for the other competitor in the antibiotics market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current antibiotics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antibiotics market growth in the coming future?

Target Audience who can be benefited from this Antibiotics Market Report Study

• Antibiotics products providers
• Research organizations and consulting companies
• Antibiotics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Antibiotics
• Various distribution channels to know more about the antibiotics market and the latest product innovations in the antibiotics market.

Frequently Asked Questions for Antibiotics Market:

1. What are Antibiotics?

Antibiotics are medicines that fight bacterial infections in people and animals. They work by killing the bacteria or by making it hard for the bacteria to grow and multiply.

2. What is the market for global Antibiotics?

The global antibiotics market was valued at USD 44.20 billion in 2023, growing at a CAGR of 4.91% during the forecast period from 2024 to 2030 to reach USD 58.90 billion by 2030.

3. What are the drivers for the global Antibiotics market?

The antibiotics market is slated to witness prosperity owing to factors such as the rising prevalence of infectious diseases, increased consumption of antibiotics in low and middle-income countries, increased research and development to develop advanced therapies, and a growing geriatric population which is susceptible to the infectious disorder are further expected to result in the appreciable revenue growth in the antibiotics market during the forecast period (2024-2030).

4. Who are the key players operating in the global Antibiotics market?

Some of the key market players operating in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Daiichi Sankyo, Astellas Pharma, Melinta Therapeutics Inc., Allergan plc., Basilea Pharmaceutical Ltd, Tetraphase Pharmaceuticals, Spero Therapeutics, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc. and others.

5. Which region has the highest share in the Antibiotics market?

Among all the regions, Asia-Pacific is expected to lead in revenue generation in the global antibiotics market. This can be ascribed to the increasing prevalence of bacterial infections in the region, increasing usage of antibiotics for various diseases, and the local presence of key market players among other factors in the region.